Published in Surgery Litigation and Law Weekly, August 17th, 2007
"We evaluated the effects of the epidermal growth factor receptor (EGFR)/HER2 inhibitor,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.